Literature DB >> 21798405

[Use of anti-VEGF (anti-vascular endothelial growth factor) in Retinopathy of Prematurity (ROP)].

I González Viejo, C Ferrer Novella, V Pueyo Royo.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21798405     DOI： 10.1016/j.oftal.2011.05.008

Source DB:  PubMed          Journal:  Arch Soc Esp Oftalmol        ISSN： 0365-6691


× No keyword cloud information.
  3 in total

1.  Intravitreal bevacizumab monotherapy for type-1 prethreshold, threshold, and aggressive posterior retinopathy of prematurity - 27 month follow-up results from Turkey.

Authors:  Huseyin Yetik; Murat Gunay; Sarkis Sirop; Ziya Salihoglu
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-12-14       Impact factor: 3.117

2.  Silibinin inhibits VEGF secretion and age-related macular degeneration in a hypoxia-dependent manner through the PI-3 kinase/Akt/mTOR pathway.

Authors:  C H Lin; C H Li; P L Liao; L S Tse; W K Huang; H W Cheng; Y W Cheng
Journal:  Br J Pharmacol       Date:  2013-02       Impact factor: 8.739

3.  The treatment and risk factors of retinopathy of prematurity in neonatal intensive care units.

Authors:  Yunxia Leng; Wenzhi Huang; Guoliang Ren; Cheng Cai; Qingbiao Tan; Yuqin Liang; Weizhong Yang; Zongyin Gao
Journal:  BMC Ophthalmol       Date:  2018-11-20       Impact factor: 2.209
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.